PROTAC CDK2/9 Degrader-1 is primarily used in research to selectively degrade CDK2 and CDK9 proteins, which are involved in cell cycle regulation and transcription. Its application is significant in studying cancer biology, as these proteins are often overactive in various cancers. By degrading CDK2 and CDK9, this compound helps researchers understand their roles in tumor growth and survival. It also serves as a tool to explore potential therapeutic strategies targeting these proteins, offering insights into developing treatments for cancers dependent on CDK2/9 activity. Additionally, it aids in investigating drug resistance mechanisms and identifying novel pathways for intervention in cancer therapy.